In addition, SELENOK promoted the subcellular trafficking of fatty acid translocase (CD36), which could elevate the fatty acid intake by facilitating the recruitment and assembly of coat protein complex II vesicles and eventually increase the distribution of CD36 on the plasma membrane to aggravate hepatic steatosis [70]. The gene discussed is CD36; the disease is fatty liver disease.